Not recruitingEUCTR 2010-018860-17
A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with depression. Other eligibility criteria apply.
- Listed locations
- Bulgaria · Estonia and 7 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 1,500
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Bulgaria, Estonia, Finland, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2010-018860-17
- Official title
Show the full official title
A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder
Recruitment & locations
Not recruitingBulgaria · Estonia · Finland
6 more locations
- Germany
- Hungary
- Italy
- Slovakia
- Spain
- Sweden
Registry details
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Who can participate?
This study is for people with depression. Other eligibility criteria apply.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ...
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...